In 2025, Chinese-made surgical robots quietly outsold imported systems for the first time in the country's public hospital tenders — a genuine inflection point in a market Frost & Sullivan projects will grow from RMB 22.45 billion in 2026 to RMB 70.85 billion by 2030, a 33.3% compound annual growth rate that dwarfs the pace of the US and European markets covered earlier in this series. Da Vinci, Hugo, and Versius aren't competing in a vacuum — a genuinely separate domestic Chinese industry has been building its own surgical robots for years, and by 2026 it's starting to show up directly in the sales numbers.
The Domestic Surge: Who's Actually Building These Robots
Shanghai MicroPort MedBot, listed on the main board of the Hong Kong Stock Exchange, makes the Toumai robotic system, now approved in nearly 10 countries and reaching more than 40% of the world's population through its various regulatory approvals. MicroPort's international credibility extends beyond paperwork: its remote surgical system performed the UK's first and Europe's longest-distance telesurgery procedure, an operation notable enough to draw BBC coverage. Shenzhen Edge Medical, which specializes in laparoscopic surgical robots (the most widely used category in clinical medicine), passed review for its Shanghai STAR Market IPO in 2023 and is building a new 60,000-square-meter Shanghai manufacturing facility with capacity for more than 500 surgical robots annually. Tinavi Medical Technologies has taken a different specialty path, focusing on orthopedic surgical robots under its Tianji brand, with systems already installed in more than 10 Chinese hospitals. Rounding out the field, Jingfeng Medical (with its MP1000 and CP1000 systems) and Cornerstone Robotics (Sentire) have joined what industry trackers describe as a genuine "first echelon" of Chinese surgical robot manufacturers.
The 2026 Sales Volume Surprise
One data point from early 2026 sales tracking is worth sitting with directly, because it inverts the usual narrative about this market: in a specific sales-volume comparison covering the first several months of 2026, Chinese domestic manufacturer Huake Precision ranked first in the industry by units sold, with 22 systems, while Yake Smart and Tinavi Medical Technologies each sold 10 units — ahead of Intuitive Surgical's 9 units and Medtronic's 8 units in the same comparison. As the data source itself put it plainly, "leading sales value does not completely equate to leading sales volume" — Intuitive and Medtronic's individual systems still command far higher prices and revenue per unit, but on pure unit count within this specific market snapshot, Chinese domestic manufacturers were genuinely outselling the two Western incumbents covered earlier in this series.
Why Now: Insurance Policy and Cost Pressure
Two structural forces are driving this shift simultaneously. China's medical insurance payment catalog policy, implemented in 2026, clarifies the reimbursement fee framework for four categories of surgical robots specifically, which industry analysts say significantly lowers the financial barrier for individual hospitals to adopt robotic surgery in the first place — a policy lever neither the US nor UK markets have applied in quite the same targeted way. At the same time, the sheer number of competing platforms, domestic and international, is expected to drive system costs down 20 to 30% by 2030 as Hugo, Versius, and the growing field of Chinese manufacturers all compete for the same hospital budgets, a dynamic that benefits hospitals and patients regardless of which specific brand ultimately wins any individual sale.
The Numbers, With an Honest Caveat About Conflicting Estimates
Different research firms size China's surgical robotics market meaningfully differently, which is worth flagging rather than picking one figure and presenting it as settled fact. Frost & Sullivan's RMB 22.45 billion 2026 estimate (roughly $3.1 billion at current exchange rates) sits alongside a separate industry estimate of $3.8 billion for 2026, representing an 11% global market share, up from just 5% in 2020 — while yet another market research estimate puts China's 2025 surgical robotics revenue at a considerably smaller $496.7 million, projecting growth to $1.77 billion by 2033. Those figures likely reflect different methodologies, scopes (some may include only certain robot categories or exclude adjacent medical robotics), and reporting periods rather than one being simply wrong — but the range itself is a useful reminder to treat any single market-size figure in this fast-moving space with some skepticism until multiple sources converge.
Where This Leaves da Vinci
None of this domestic Chinese growth means Intuitive Surgical is losing its broader global position — North America still accounts for roughly 60 to 65% of the entire global surgical robotics market, a scale China's fast-growing but still much smaller market hasn't approached. Industry analysts project China will become the world's second-largest surgical robotics market by 2028, and Intuitive and Medtronic are both actively expanding their direct presence in China rather than ceding the market to domestic competitors. The more accurate read isn't "China is overtaking da Vinci" — it's that a genuinely separate, fast-growing, increasingly capable domestic industry now exists inside what used to be an overwhelmingly import-dependent market, adding a fourth major competitive front to the da Vinci-Hugo-Versius story covered earlier in this series.
China's Surgical Robot Market at a Glance
| Company | Specialty | Notable milestone |
|---|---|---|
| Shanghai MicroPort MedBot | General laparoscopic (Toumai) | Approved in ~10 countries; performed UK's first telesurgery |
| Shenzhen Edge Medical | Laparoscopic surgery | New 500+ unit/year Shanghai manufacturing facility |
| Tinavi Medical Technologies | Orthopedic (Tianji) | Installed in 10+ Chinese hospitals |
| Huake Precision | Not specified in available data | Ranked #1 in China by unit sales volume, early 2026 |
Frequently Asked Questions
Are Chinese-made surgical robots actually outselling da Vinci?
In terms of unit sales volume within China's domestic market during early 2026, yes — Chinese manufacturers Huake Precision, Yake Smart, and Tinavi each outsold Intuitive Surgical and Medtronic in units sold, though Intuitive's systems still generate far higher revenue per unit globally.
How big is China's surgical robotics market expected to become?
Estimates vary by source, but Frost & Sullivan projects the market will grow from RMB 22.45 billion in 2026 to RMB 70.85 billion by 2030, a 33.3% compound annual growth rate. China is projected to become the world's second-largest surgical robotics market by 2028.
What is MicroPort MedBot's Toumai system?
Toumai is a general laparoscopic surgical robot made by Shanghai MicroPort MedBot, approved in nearly 10 countries and reaching more than 40% of the world's population through its regulatory approvals, and used to perform the UK's first and Europe's longest-distance telesurgery.
Is da Vinci losing its global market position to Chinese manufacturers?
Not overall. North America still accounts for roughly 60 to 65% of the global surgical robotics market. Chinese domestic manufacturers are growing quickly within China specifically, adding a new competitive front rather than displacing Intuitive Surgical's broader global position.